Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Lagevrio 200 mg hard capsules
⚠ This medicine appears to have been discontinued
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Molnupiravir may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
What it is and what it is used for
for
Lagevrio contains the active substance molnupiravir. Lagevrio is an antiviral medicine used to treat mild to moderate COVID-19 (caused by SARS-CoV-2) in adults who are at risk for developing severe illness. Lagevrio may help people with COVID-19 stay out of the hospital and feel better. 2.
What you need to know before you take it
e Lagevrio
Do not take Lagevrio if you are allergic to molnupiravir or any of the other ingredients of this medicine (listed in section 6). Warnings and precautions Talk to your doctor or pharmacist before taking molnupiravir. During treatment, if you experience an allergic reaction (such as swelling of the mouth, lips or face, difficulty in breathing or swallowing, skin rash, reddening of the skin), contact your doctor straight away as you may need urgent medical treatment. Children and adolescents Do not give this medicine to children and adolescents aged less than 18 years. The use of Lagevrio in persons aged less than 18 years has not yet been studied.
Other medicines and Lagevrio Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Pregnancy and breast-feeding Animal studies with molnupiravir have shown harmful effects to the unborn animal. Lagevrio is not recommended in pregnancy. Lagevrio has not been studied in pregnancy and it is not known if Lagevrio will harm your baby while you are pregnant. If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor for advice. If you can become pregnant, you should use effective birth control while you are taking Lagevrio and for 4 days after the last dose of Lagevrio. If you are breast-feeding or are planning to breastfeed, tell your doctor before taking this medicine. Breast-feeding is not recommended during treatment and for 4 days after the last dose of Lagevrio. This is because it is not known if Lagevrio gets into breast milk and will be passed to the baby. Driving and using machines No studies on the effects on the ability to drive and use machines have been performed. Lagevrio contains sodium This medicine contains less than 1 mmol sodium (23 mg) per dose of 4 capsules, that is to say essentially 'sodium-free'. 3.
How to take Lagevrio
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. You should start Lagevrio within 5 days of the onset of COVID-19 symptoms. How much to take The recommended dose of Lagevrio is four 200 mg capsules, every 12 hours for 5 days. It is important that you complete the full 5 days of treatment with molnupiravir. Do not stop taking molnupiravir before you complete the full 5 days of treatment, even if you feel better.
How to take it
• Swallow the capsule whole with plenty of fluid (for instance a glass of water) • This medicine can be taken with or without food. If you take more Lagevrio than you should If you take more Lagevrio than you should, contact your doctor straight away. If you forget to take Lagevrio • It is important that you do not miss or skip doses of this medicine. • If you forget to take a dose within 10 hours of the time it is usually taken, you should take it as soon as possible and take the next one at the usual time. • If you forget to take a dose by more than 10 hours, you should not take the missed dose and instead take the next one at the usual time. • Do not take a double dose to make up for a missed dose. • If you are not sure what to do, call your doctor or pharmacist.
Do not stop taking Lagevrio Do not stop taking Lagevrio without talking to your doctor first. This will give the medicine the best chance to keep you from becoming severely ill from COVID-19. If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 4.
Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them. Common: may affect up to 1 in 10 people
- diarrhoea
- nausea
- feeling dizzy Uncommon: may affect up to 1 in 100 people
- allergic reactions including rash, hives and swelling of the mouth, lips or face
- redness of the skin
- headache
- vomiting
- itching Reporting of side effects If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Coronavirus Yellow Card Reporting site at https://coronavirus-yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine. 5.
How to store it
Lagevrio
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and bottle label after EXP. The expiry date refers to the last day of that month. This medicinal product does not require any special temperature storage conditions. Store in the original package. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment. 6.
Contents of the pack and other information
What Lagevrio contains The active substance is molnupiravir. Each hard capsule contains 200 mg of molnupiravir. The other ingredients are: Capsule content: Croscarmellose sodium (E468), hydroxypropyl cellulose (E463), magnesium stearate (E470b), microcrystalline cellulose (E460).
Capsule shell: Hypromellose (E464), titanium dioxide (E171), red iron oxide (E172). Printing ink: Butyl alcohol, dehydrated alcohol, isopropyl alcohol, potassium hydroxide, propylene glycol (E1520), purified water, shellac, strong ammonia solution, and titanium dioxide (E171). What Lagevrio looks like and contents of the pack Lagevrio 200 mg hard capsule is a Swedish Orange opaque, size 0 (approximately 21.7 mm x 7.6 mm) hard capsule, printed with MSD corporate logo on the cap and "82" on the body in white ink. Lagevrio 200 mg hard capsules are supplied in high-density polyethylene (HDPE) bottles with a polypropylene cap containing 40 capsules. Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder: Merck Sharp & Dohme (UK) Limited 120 Moorgate London EC2M 6UR United Kingdom Manufacturer: Merck Sharp & Dohme B.V. Waarderweg 39 2031 BN Haarlem The Netherlands For any information about this medicine, please contact: Merck Sharp & Dohme (UK) Limited Tel: +44 (0) 208 154 8000 [email protected] This leaflet was last revised in October 2025 This medicinal product has been authorised under 'exceptional circumstances'. This means that it has not been possible to obtain complete information on this medicinal product. The Medicines and Healthcare product Regulatory Agency (MHRA) will review any new information which may become available every year and this leaflet will be updated as necessary. Other sources of information
www.molnupiravir.com/uk © 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. New MAA + REG267
Frequently asked questions about Lagevrio 200 mg hard capsules
How do I take Lagevrio 200 mg hard capsules?
Lagevrio 200 mg hard capsules comes as capsule containing 200mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
What is the active substance in Lagevrio 200 mg hard capsules?
The active substance in Lagevrio 200 mg hard capsules is molnupiravir.
Where does this information come from?
This leaflet reproduces the patient information leaflet approved for Lagevrio 200 mg hard capsules, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Can I get Lagevrio 200 mg hard capsules without a prescription?
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
About this leaflet
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
- Source: electronic medicines compendium (emc), Datapharm
- Active substance: molnupiravir
- Official document: view the original leaflet on emc →
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
4.1. Therapeutic indications
Lagevrio is indicated for treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults with a positive SARS-CoV-2 diagnostic test and who have at least one risk factor for developing severe illness (see sections 4.2 and 5.1 for information on posology and limits of clinical trial population).
4.2. Posology and method of administration
Posology
Adults
The recommended dose of Lagevrio is 800 mg (four 200 mg capsules) taken orally every 12 hours for 5 days.
The safety and efficacy of molnupiravir when administered for periods longer than 5 days have not been established (see section 5.1).
Lagevrio should be administered as soon as possible after a diagnosis of COVID-19 has been made and within 5 days of symptom onset (see section 5.1).
Missed dose
If the patient misses a dose of Lagevrio within 10 hours of the time it is usually taken, the patient should take as soon as possible and resume the normal dosing schedule. If a patient misses a dose by more than 10 hours, the patient should not take the missed dose and instead take the next dose at the regularly scheduled time. The patient should not double the dose to make up for a missed dose.
Special populations
Elderly
No dose adjustment of Lagevrio is required based on age (see section 5.2).
Renal impairment
No dose adjustment is required for patients with renal impairment (see section 5.2).
Hepatic impairment
No dose adjustment is required for patients with hepatic impairment (see section 5.2).
Paediatric population
The safety and efficacy of Lagevrio in patients below 18 years of age have not been established. No data are available (see section 5.1).
Method of administration
For oral use.
Lagevrio 200 mg capsules can be taken with or without food.
The capsules should be swallowed whole with a sufficient amount of fluid (e.g., a glass of water). The capsules should not be opened, crushed or chewed.
4.3. Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
4.4. Special warnings and precautions for use
Hypersensitivity
Hypersensitivity reactions have been reported with Lagevrio (see section 4.8). If signs or symptoms of a clinically significant hypersensitivity reaction occur, immediately discontinue Lagevrio and initiate appropriate medications and/or supportive care.
Sodium
This medicinal product contains less than 1 mmol sodium (23 mg) per dose of 4 capsules, that is to say essentially 'sodium‑free'.
4.5. Interaction with other medicinal products and other forms of interaction
No drug interactions have been identified based on the limited available data. No clinical interaction studies have been performed with molnupiravir. Molnupiravir is hydrolysed to N4-hydroxycytidine (NHC) prior to reaching systemic circulation. Uptake of NHC and metabolism to NHC-TP are mediated by the same pathways involved in endogenous pyrimidine metabolism. NHC is not a substrate of major drug metabolising enzymes or transporters. Based on in vitro studies, neither molnupiravir nor NHC are inhibitors or inducers of major drug metabolising enzymes or inhibitors of major drug transporters. Therefore, the potential for molnupiravir or NHC to interact with concomitant medications is considered unlikely.
4.6. Fertility, pregnancy and lactation
Pregnancy
There are no data from the use of Lagevrio in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3).
Lagevrio is not recommended during pregnancy. Women of childbearing potential should use effective contraception for the duration of treatment and for 4 days after the last dose of Lagevrio (molnupiravir).
Breast-feeding
It is unknown whether molnupiravir or any of the metabolites of molnupiravir are present in human milk, affect human milk production, or have effect on the breastfed infant. NHC was detected in the plasma of nursing pups from lactating rats administered molnupiravir (see section 5.3).
Based on the potential for adverse reactions on the infant from Lagevrio, breast-feeding is not recommended during treatment and for 4 days after the last dose of Lagevrio.
Fertility
There were no effects on female or male fertility in rats at NHC exposures approximately 2 and 6 times respectively, the exposure in humans at the recommended human dose (RHD) (see section 5.3).
4.7. Effects on ability to drive and use machines
No studies on the effects on the ability to drive and use machines have been performed.
4.8. Undesirable effects
Summary of safety profile
Data from a Phase 3 trial of subjects with mild to moderate COVID-19 treated with molnupiravir (n=710), the most common adverse reactions (≥1% of subjects) reported during treatment and during 14 days after the last dose were diarrhoea (2%), nausea (1%) and dizziness (1%) all of which were Grade 1 (mild) or Grade 2 (moderate).
Tabulated list of adverse reactions
Adverse reactions in the Phase 3 trial and post marketing experience are listed below by system organ class and frequency. Frequencies are defined as follows: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000).
Table 1: Tabulated list of adverse reactions
Frequency
Adverse Reaction
Immune System Disorders
Uncommon
hypersensitivity
Nervous system disorders
Common
dizziness
Uncommon
headache
Gastrointestinal disorders
Common
diarrhoea, nausea
Uncommon
vomiting
Skin and subcutaneous tissue disorders
Uncommon
angioedema, erythema, rash, urticaria, pruritus
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Coronavirus Yellow Card Reporting site at https://coronavirus-yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.
4.9. Overdose
There is no human experience of overdosage with Lagevrio. Treatment of overdose with Lagevrio should consist of general supportive measures including the monitoring of the clinical status of the patient. Haemodialysis is not expected to result in effective elimination of NHC.
💬 Ask about this leaflet
Ask anything about Lagevrio 200 mg hard capsules. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.